A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker - 15/08/11
Corresponding author. Department of Pulmonology, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands. Tel.: +310306092428; fax: +31306096052001.Summary |
Background |
YKL-40, a chitinase-like cartilage glycoprotein, has recently shown its potential as a marker for sarcoidosis.
Methods |
This study aimed to assess whether YKL-40 at presentation may predict the course of sarcoidosis over a 4-year follow-up period and to investigate whether polymorphisms in the chitinase 3-like 1 (CHI3L1) gene might influence serum YKL-40 levels in sarcoidosis patients (
) and controls (
).
Results |
Patients had significantly higher (mean, 95% CI) serum YKL-40 levels (181.3ng/ml, 50.7–648.1) compared to controls (36.6ng/ml, p<0.0001. Serum YKL-40 was elevated in 79% of the patients and was inversely correlated with DLco at presentation (
, 
), but not after 2–4 years of follow-up (
, 
). Serum YKL-40 levels in controls were dependent on the CHI3L1 −329 G/A polymorphism (mean, 95% CI): GG (
) 48.3ng/ml, 41.7–56.0; GA (
) 31.2ng/ml, 26.6–36.3; AA (
) 17.8ng/ml, 13.6–23.4, p<0.0001. In patients, this effect was not observed.
Conclusions |
YKL-40 may be used as a sarcoidosis disease marker, but it is unsuitable as a marker to predict the course of the disease. The CHI3L1 −329 G/A polymorphism contributes to inter-individual variations of YKL-40 levels, but does not influence sarcoidosis disease susceptibility or severity.
Le texte complet de cet article est disponible en PDF.Keywords : CHI3L1, Fibrosis, Genetics, Sarcoidosis, Single nucleotide polymorphism, YKL-40
Plan
Vol 101 - N° 7
P. 1563-1571 - juillet 2007 Retour au numéro
Article précédent
- Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension
- Hsao-Hsun Hsu, Jin-Shing Chen, Robert J. Chen, Wen-Je Ko, Shuenn-Wen Kuo, En-Ting Wu, Mei-Hwan Wu, Jou-Kou Wang, Yung-Chie Lee
- Prophylactic use of noninvasive ventilation in patients undergoing lung resectional surgery
- Christophe Perrin, Valérie Jullien, Nicolas Vénissac, Frédéric Berthier, Bernard Padovani, Françoise Guillot, Alain Coussement, Jérôme Mouroux
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?